Spiro Medical Inc.

Based in the US, Spiro Medical develops advanced medical technologies aimed at treating respiratory conditions, focusing on innovative neuromodulation solutions for chronic issues such as asthma and COPD. Founded in 2023, Spiro Medical is dedicated to creating medical solutions for respiratory conditions. The firm made its debut with the Spiro Neuromodulation System and has since raised USD 67. 00 million in Series A funding on January 7, 2026, led by Andera Partners and Omega Funds, among others.

The company operates from its headquarters in the US. Spiro Medical specializes in advanced medical solutions targeting respiratory conditions like asthma, chronic cough, and chronic obstructive pulmonary disease (COPD). Their core product, the Spiro Neuromodulation System, provides a non-pharmacological intervention by modulating neural pathways involved in respiratory function, aiming to improve patients' quality of life. Their offerings primarily serve healthcare institutions including hospitals and specialty clinics across North America and Europe.

Spiro Medical generates revenue through direct sales and partnerships with healthcare providers. They supply the Spiro Neuromodulation System to hospitals and clinics, emphasizing long-term partnerships that may include training and support services. While pricing details remain proprietary, the sales model is designed to foster ongoing relationships with clients. Spiro Medical plans to utilize the recent USD 67.

00 million raised in Series A funding to develop a purpose-built pulmonary neuromodulation system and conduct clinical work for regulatory approval in the US. The company aims to expand its reach into additional healthcare markets across North America and Europe, focusing on increasing the availability of their innovative solutions by the end of 2026.